51509-99-0

Upstream product

• 51509-98-9 8-Phenyl-1,4-dioxaspiro<4.5>decan-8-carbonitril 
• 75945-89-0 2.2-Bis-β-chlorethyl-1.3-dioxolan 
• 25288-77-1 8-(4-chloro-phenyl)-1,4-dioxa-spiro[4.5]decane-8-carbonitrile 
• 140-29-4 phenylacetonitrile 
• 3592-25-4 1,5-dichloropentan-3-one 

Downstream Products

• 75945-91-4 4-oxo-1-phenylcyclohexanecarboxylic acid 
• 65619-17-2 4-isocyanato-4-phenylcyclohexanone, ethylene ketal 
• 51510-02-2 4-acetoxymethyl-4-phenylcyclohexanone 
• 51510-01-1 4-(hydroxymethyl)-4-phenylcyclohexanone 
• 75945-93-6 (cis-4-Methylamino-1-phenyl)-cyclohexancarbonsaeuremethylester 
• 75945-92-5 4-Methylamino-1-phenyl-cyclohexancarbonsaeuremethylester 
• 75945-94-7 4-Benzylamino-1-phenyl-cyclohexancarbonsaeuremethylester 
• 75945-95-8 2-Benzyl-4-phenyl-2-azabicyclo<2.2.2>octan-3-on 
• 75945-96-9 2-Benzyl-4-phenyl-2-azabicyclo<2.2.2>octan 
• 75945-90-3 4-Oxo-1-phenyl-cyclohexancarbonsaeuremethylester 
• 63383-64-2 2-Methyl-4-phenyl-2-azabicyclo<2.2.2>octan-3-on 
• 63383-74-4 2-Methyl-4-phenyl-2-azabicyclo<2.2.2>octan 
• 1189796-24-4 8-phenyl-1,4-dioxa-spiro[4.5]decane-8-carboxylic acid-butyl-methylamide 
• 1189796-19-7 8-phenyl-1,4-dioxa-spiro[4.5]decane-8-carboxylic acid-benzyl-methylamide 

Relevant academic research and scientific papers

Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors

The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models.

Spirocyclic Azaindole Derivatives

The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments.

SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Benzamide derivatives and uses related thereto

Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, and n are as defined herein.

Synthesis and Reactivity of 4-Phenylisoquinuclidines

Several approaches to the synthesis of the 2-alkyl-4-phenylisoquinuclidines 14 and 15, the 3,4-diphenylisoquinuclidines 22-24 and of 6-oxo-4-phenyl-3-isoquinuclidone (43) are described.The structure of the products of hydrolysis of 7-phenyl-1,4-dioxaspirodecanecarboxamide (36) were determined by spectroscopy and degradative reactions.

4-Amino-4-phenylcyclohexanone ketal compositions and process of use

A class of new 4-amino-4-arylcyclohexanones, their ketals, and acid addition salts have been synthesized and found to be useful for relieving pain in animals. Their analgesic activity appears to be of high order, and in addition some exhibit narcotic antagonist activity that is useful in modifying the cardiovascular, respiratory, and behavioral depression caused by other analgesics. Several show mixed analgesic and narcotic antagonist activity. Preferred compounds of the class are 4-(m-hydroxyphenyl)-4-dimethylaminocyclohexanone ethylene ketal, and 4-(m-hydroxyphenyl)-4-(n-butylmethylamino)cyclohexanone ethylene ketal as free bases and as their hydrochloride salts. Processes for synthesis and intermediates are described. Unit dosage forms and therapeutic treatments are disclosed.

4-Arylcyclohexylamines

The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula SPC1 Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, EQU1 WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R1 and R2 taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.